4.5 Review

G Protein-Coupled Receptor (GPCR) Expression in Native Cells: Novel endoGPCRs as Physiologic Regulators and Therapeutic Targets

期刊

MOLECULAR PHARMACOLOGY
卷 88, 期 1, 页码 181-187

出版社

AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/mol.115.098129

关键词

-

资金

  1. National Institutes of Health [CA189477, CA121938, GM68524, HL091061, HL066941, HL007444, GM-68524]
  2. Department of Defense [W81XWH-14-1-0372]
  3. Roche
  4. Pfizer-CovX
  5. Bristol Myers Squibb
  6. American Heart Association
  7. ASPET-Astellas Award in Translational Pharmacology

向作者/读者索取更多资源

Gprotein-coupled receptors (GPCRs), the largest family of signaling receptors in the human genome, are also the largest class of targets of approved drugs. Are the optimal GPCRs (in terms of efficacy and safety) currently targeted therapeutically? Especially given the large number (similar to 120) of orphan GPCRs (which lack known physiologic agonists), it is likely that previously unrecognized GPCRs, especially orphan receptors, regulate cell function and can be therapeutic targets. Knowledge is limited regarding the diversity and identity of GPCRs that are activated by endogenous ligands and that native cells express. Here, we review approaches to define GPCR expression in tissues and cells and results from studies using these approaches. We identify problems with the available data and suggest future ways to identify and validate the physiologic and therapeutic roles of previously unrecognized GPCRs. We propose that a particularly useful approach to identify functionally important GPCRs with therapeutic potential will be to focus on receptors that show selective increases in expression in diseased cells from patients and experimental animals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据